Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Fibroblast growth factor 21202 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00278 | 35154523 | Arch Med Sci | Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss. | 2021 | Details |
| A00386 | 35107741 | Mol Biol Rep | Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling. | 2022 | Details |
| A00467 | 35070009 | World J Hepatol | Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis. | 2021 | Details |
| A00539 | 35052640 | Antioxidants (Basel) | Phytochemicals from the Cocoa Shell Modulate Mitochondrial Function, Lipid and Glucose Metabolism in Hepatocytes via Activation of FGF21/ERK, AKT, and mTOR Pathways. | 2022 | Details |
| A00559 | 35046901 | Front Endocrinol (Lausanne) | The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model. | 2022 | Details |
| A00597 | 35035378 | Front Endocrinol (Lausanne) | Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity. | 2021 | Details |
| A00623 | 35024308 | Acta Pharm Sin B | Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liver. | 2021 | Details |
| A00650 | 35014168 | Basic Clin Pharmacol Toxicol | Efficacy of fibroblast growth factor 21 in non-alcoholic fatty liver disease in guinea pigs. | 2022 | Details |
| A00760 | 34977519 | JHEP Rep | Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. | 2021 | Details |
| A00818 | 34957498 | Diabetes | Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk via Induction of FGF21 in Mice. | 2021 | Details |
| A00872 | 34943946 | Cells | Fibroblast Growth Factor 21 (FGF21) Administration Sex-Specifically Affects Blood Insulin Levels and Liver Steatosis in Obese Ay Mice. | 2021 | Details |
| A00963 | 34917917 | Metabol Open | Emerging roles for stress kinase p38 and stress hormone fibroblast growth factor 21 in NAFLD development. | 2021 | Details |
| A01114 | 34866842 | J Clin Exp Hepatol | Adipocytokines as Risk Factors for Development of Nonalcoholic Fatty Liver Disease in Children. | 2021 | Details |
| A01256 | 34813496 | Physiol Int | Effect of vanillic acid and exercise training on fatty liver and insulin resistance in rats: Possible role of fibroblast growth factor 21 and autophagy. | 2021 | Details |
| A01374 | 34769488 | Int J Mol Sci | The Roles of Carbohydrate Response Element Binding Protein in the Relationship between Carbohydrate Intake and Diseases. | 2021 | Details |
| A01537 | 34706542 | J Agric Food Chem | Sulforaphane Regulates Glucose and Lipid Metabolisms in Obese Mice by Restraining JNK and Activating Insulin and FGF21 Signal Pathways. | 2021 | Details |
| A01635 | 34675003 | Diabetes | Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk via Induction of FGF21 in Mice. | 2021 | Details |
| A01668 | 34660809 | J Diabetes Res | Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01685 | 34654875 | Acta Pharmacol Sin | Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway. | 2021 | Details |
| A02242 | 34448598 | Metab Syndr Relat Disord | Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake. | 2021 | Details |
| A02300 | 34431493 | J Clin Endocrinol Metab | LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. | 2022 | Details |
| A02320 | 34420934 | Gut Liver | Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A02570 | 34326695 | Int J Biol Sci | Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice. | 2021 | Details |
| A02792 | 34239138 | Nat Med | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. | 2021 | Details |
| A03322 | 34046014 | Front Endocrinol (Lausanne) | Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice. | 2021 | Details |
| A03770 | 33869312 | Front Cardiovasc Med | The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases. | 2021 | Details |
| A03843 | 33851458 | Hepatology | Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. | 2021 | Details |
| A04000 | 33794741 | Autophagy | The ménage à trois of autophagy, lipid droplets and liver disease. | 2021 | Details |
| A04343 | 33657443 | Contemp Clin Trials | The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. | 2021 | Details |
| A04809 | 33498410 | J Clin Med | Hepatokines as a Molecular Transducer of Exercise. | 2021 | Details |
| A04993 | 33421947 | EBioMedicine | A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. | 2021 | Details |
| A05091 | 33381084 | Front Endocrinol (Lausanne) | FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. | 2020 | Details |
| A05107 | 33373666 | Diabetes Metab | Dose-response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease. | 2020 | Details |
| A05499 | 33229553 | Proc Natl Acad Sci U S A | Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease. | 2020 | Details |
| A06125 | 32997872 | Mol Nutr Food Res | CREBH: A Complex Array of Regulatory Mechanisms in Nutritional Signaling, Metabolic Inflammation, and Metabolic Disease. | 2020 | Details |
| A06322 | 32929325 | Theranostics | Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. | 2020 | Details |
| A06563 | 32824349 | Antioxidants (Basel) | Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A06805 | 32738448 | J Hepatol | Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity. | 2020 | Details |
| A06853 | 32723353 | BMC Res Notes | Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21. | 2020 | Details |
| A06854 | 32721044 | FASEB J | Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease. | 2020 | Details |
| A06888 | 32708435 | Nutrients | Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study. | 2020 | Details |
| A06951 | 32688339 | Endocr Connect | FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. | 2020 | Details |
| A07028 | 32652799 | Liver Int | High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels. | 2020 | Details |
| A07477 | 32481431 | Medicine (Baltimore) | Simple resistance exercise decreases cytokeratin 18 and fibroblast growth factor 21 levels in patients with nonalcoholic fatty liver disease: A retrospective clinical study. | 2020 | Details |
| A07788 | 32354858 | Diabetes | The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates. | 2020 | Details |
| A08165 | 32220662 | Atherosclerosis | Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease. | 2020 | Details |
| A08586 | 32049638 | BMJ Open Diabetes Res Care | Insulin resistance, beta-cell function, adipokine profiles and cardiometabolic risk factors among Chinese youth with isolated impaired fasting glucose versus impaired glucose tolerance: the BCAMS study. | 2020 | Details |
| A08802 | 31980251 | Trends Pharmacol Sci | Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08900 | 31948295 | Expert Opin Investig Drugs | Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? | 2020 | Details |
| A09026 | 31899984 | Expert Opin Investig Drugs | Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A09365 | 31776449 | Acta Pharmacol Sin | Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. | 2019 | Details |
| A09587 | 31685793 | Nutr Diabetes | Energy restriction in obese women suggest linear reduction of hepatic fat content and time-dependent metabolic improvements. | 2019 | Details |
| A09621 | 31672443 | Metabolism | Fibroblast growth factor 21 in non-alcoholic fatty liver disease. | 2019 | Details |
| A09634 | 31668386 | Mol Metab | Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice. | 2019 | Details |
| A09686 | 31648561 | FASEB J | KLF15-activating Twist2 ameliorated hepatic steatosis by inhibiting inflammation and improving mitochondrial dysfunction via NF-κB-FGF21 or SREBP1c-FGF21 pathway. | 2019 | Details |
| A10235 | 31419414 | Clin Chim Acta | Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. | 2019 | Details |
| A10475 | 31322211 | Mol Med Rep | Ascorbic acid attenuates cell stress by activating the fibroblast growth factor 21/fibroblast growth factor receptor 2/adiponectin pathway in HepG2 cells. | 2019 | Details |
| A10564 | 31289229 | Proc Natl Acad Sci U S A | YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. | 2019 | Details |
| A10822 | 31173200 | Mol Med Rep | Diallyl disulfide attenuates non‑alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, lipid peroxidation and inflammation in mice. | 2019 | Details |
| A10894 | 31136662 | Am J Clin Nutr | Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. | 2019 | Details |
| A11107 | 31039348 | Exp Cell Res | Epoxyeicosatrienoic intervention improves NAFLD in leptin receptor deficient mice by an increase in PGC1α-HO-1-PGC1α-mitochondrial signaling. | 2019 | Details |
| A11273 | 30964704 | Am J Physiol Endocrinol Metab | Role of exercise-induced hepatokines in metabolic disorders. | 2019 | Details |
| A11387 | 30916873 | Liver Int | Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. | 2019 | Details |
| A11401 | 30912255 | Liver Int | Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. | 2019 | Details |
| A11549 | 30848827 | J Clin Endocrinol Metab | Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. | 2019 | Details |
| A11779 | 30747091 | Curr Mol Pharmacol | Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone. | 2019 | Details |
| A12182 | 30572788 | Biosci Biotechnol Biochem | A review of the studies on food-derived factors which regulate energy metabolism via the modulation of lipid-sensing nuclear receptors. | 2018 | Details |
| A12231 | 30554783 | Lancet | Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. | 2018 | Details |
| A12297 | 30520566 | Obesity (Silver Spring) | Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. | 2018 | Details |
| A12446 | 30453990 | J Transl Med | Deficiency in interleukin-18 promotes differentiation of brown adipose tissue resulting in fat accumulation despite dyslipidemia. | 2018 | Details |
| A12640 | 30355361 | Lipids Health Dis | Sleeve gastrectomy attenuates high fat diet-induced non-alcoholic fatty liver disease. | 2018 | Details |
| A13443 | 29971527 | Diabetologia | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. | 2018 | Details |
| A13578 | 29898429 | Biomed Pharmacother | Cyanidin-3-O-β-glucoside regulates the activation and the secretion of adipokines from brown adipose tissue and alleviates diet induced fatty liver. | 2018 | Details |
| A13791 | 29753678 | Mol Metab | Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. | 2018 | Details |
| A13796 | 29751292 | J Nutr Biochem | Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance. | 2018 | Details |
| A13995 | 29653185 | Biochim Biophys Acta Mol Basis Dis | Sex differences in the development of hepatic steatosis in cafeteria diet-induced obesity in young mice. | 2018 | Details |
| A14270 | 29491146 | J Biol Chem | Mice lacking ARV1 have reduced signs of metabolic syndrome and non-alcoholic fatty liver disease. | 2018 | Details |
| A14642 | 29311481 | Biol Pharm Bull | A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation. | 2018 | Details |
| A14680 | 29289645 | Mol Metab | Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. | 2017 | Details |
| A15077 | 29107287 | Mol Metab | Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. | 2017 | Details |
| A15701 | 28752050 | Mol Metab | Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders. | 2017 | Details |
| A15810 | 28698650 | Sci Rep | Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16080 | 28580278 | Mol Metab | FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis. | 2017 | Details |
| A16171 | 28525362 | Horm Mol Biol Clin Investig | FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. | 2017 | Details |
| A16403 | 28415887 | Free Radic Res | Amelioration of late-onset hepatic steatosis in IDH2-deficient mice. | 2017 | Details |
| A16538 | 28326329 | Biomed Res Int | Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2017 | Details |
| A16844 | 28131861 | Toxicology | Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: The role of the PPARα-FGF21 axis. | 2017 | Details |
| A17199 | 27917437 | Cell Tissue Res | Nicotine plus a high-fat diet triggers cardiomyocyte apoptosis. | 2016 | Details |
| A17223 | 27904677 | Am J Transl Res | An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. | 2016 | Details |
| A17442 | 27784782 | J Biol Chem | Glucocorticoid Receptor β Induces Hepatic Steatosis by Augmenting Inflammation and Inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) α. | 2016 | Details |
| A17491 | 27765690 | Gastroenterology | Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. | 2016 | Details |
| A17735 | 27631137 | Diabetologia | The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice. | 2016 | Details |
| A17913 | 27482056 | Mol Pharmacol | A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A17932 | 27470139 | Sci Rep | Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. | 2016 | Details |
| A17986 | 27435856 | Mol Cell Biochem | FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. | 2016 | Details |
| A18194 | 27293995 | Am J Cancer Res | Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. | 2016 | Details |
| A18328 | 27207510 | Diabetes | Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD. | 2016 | Details |
| A18367 | 27179781 | Biochem Biophys Res Commun | NS5ATP6 modulates intracellular triglyceride content through FGF21 and independently of SIRT1 and SREBP1. | 2016 | Details |
| A18505 | 27085971 | Biochim Biophys Acta | BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity. | 2016 | Details |
| A18575 | 27051596 | BBA Clin | Implication of hepatokines in metabolic disorders and cardiovascular diseases. | 2016 | Details |